Searched for
APRICA PHARMACEUTICALS PVT LTD
These midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 22%, according to analystsAfter almost a period of a month and half, the mid-cap stocks have been trying to make a comeback.If one looks at the March data for the mu...- Stock picks of the week: 4 stocks with consistent score improvement and upside potential of up to 22%As broader market indices, sensex and nifty continue to form new highs some minor consolidation is happening in markets. During this period...
- These midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- These midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- These midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Midcap stocks with ‘strong buy’ & ‘buy’ recos that can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Midcap stocks with ‘strong buy’ & ‘buy’ recos can rally up to 55%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Midcap stocks with ‘strong buy’ & ‘buy’ recos can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Midcap stocks with ‘strong buy’ & ‘buy’ reco which can rally over 25%, according to analystsET screener powered by Refinitiv’s Stock Report Plus lists down quality stocks with high upside potential over the next 12 months, having a...
- Even as bears stay in control of Nifty, midcap stocks with ‘strong buy’ & ‘buy’ ratings can rally over 25%, say analystsNifty in a correction mode and how much time it will stay in that mode, it is anyone's guess. For all those who are busy guessing how thing...
- Patent row: Merck gets interim relief from HCThe Delhi High Court has restrained an Indian pharmaceutical company from launching its diabetes drug manufactured by Merck Sharp and Dohme...
- US drugmaker MSD gets interim relief on diabetes drug patent rowThe US pharma major alleged the Indian company was coming out with the diabetes drug with Sitagliptin molecule and its derivatives salt in ...
Load More
